| Autor: |
Clarke OJ; Department of Chemistry, Saint Mary's University , Halifax, Nova Scotia Canada , B3H 3C3., Goodall BL; MedMira Laboratories Inc. , Halifax, Nova Scotia, Canada , B3S 1B3., Hui HP; MedMira Laboratories Inc. , Halifax, Nova Scotia, Canada , B3S 1B3., Vats N; MedMira Laboratories Inc. , Halifax, Nova Scotia, Canada , B3S 1B3., Brosseau CL; Department of Chemistry, Saint Mary's University , Halifax, Nova Scotia Canada , B3H 3C3. |
| Abstrakt: |
Point-of-care (POC) diagnostic testing platforms are a growing sector of the healthcare industry as they offer the advantages of rapid provision of results, ease of use, reduced cost, and the ability to link patients to care. While many POC tests are based on chromatographic flow assay technology, this technology suffers from a lack of sensitivity along with limited capacity for multiplexing and quantitative analysis. Several recent reports have begun to investigate the feasibility of coupling chromatographic flow platforms to more advanced read-out technologies which in turn enable on-site acquisition, storage, and transmission of important healthcare metrics. One such technology being explored is surface-enhanced Raman spectroscopy or SERS. In this work, SERS is coupled for the first time to a rapid vertical flow (RVF) immunotechnology for detection of anti-HCV antibodies in an effort to extend the capabilities of this commercially available diagnostic platform. High-quality and reproducible SERS spectra were obtained using reporter-modified gold nanoparticles (AuNPs). Serial dilution studies indicate that the coupling of SERS with RVF technology shows enormous potential for next-generation POC diagnostics. |
